Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis.

Background: Tivozanib is a licensed as first-line treatment for metastatic renal cell carcinoma (mRCC).

Objective: To evaluate the outcomes from tivozanib in a real-world mRCC population.

Patients And Methods: Patients with mRCC commencing first-line tivozanib between March 2017 and May 2019 were identified across four specialist cancer centres in the UK.